ESR1 and breast cancer: Although fulvestrant reduced uterine weight (Additional file 2: Fig. S1B), it did not inhibit growth of these anti-estrogen resistant mammary cancers [26], nor did it increase survival (Fig. 1C-K), similar to resistant advanced clinical ER+ cancers.